Attached files
file | filename |
---|---|
8-K - FORM 8-K - Endo International plc | d81465d8k.htm |
EX-99.2 - EX-99.2 - Endo International plc | d81465dex992.htm |
Exhibit 99.1
FOR IMMEDIATE RELEASE
ENDO PROVIDES INFORMATIONAL
FREQUENTLY ASKED QUESTIONS & ANSWERS
DUBLIN, November 9, 2015 Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced that it has provided an informational Frequently Asked Questions & Answers (Q&A) document designed for investors to learn more about the Company. This Q&A is available on the Investor Relations section of Endos website at www.endo.com.
About Endo International plc
Endo International plc (NASDAQ: ENDP) (TSX: ENL) is a global specialty pharmaceutical company focused on improving patients lives while creating shareholder value. Endo develops, manufactures, markets and distributes quality branded and generic pharmaceutical products as well as over-the-counter medications though its operating companies. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA. Learn more at www.endo.com.
SOURCE Endo International plc
Investors/Media: Keri P. Mattox, (484) 216-7912; Media: Heather Zoumas-Lubeski, (484) 216-6829
#####
1